Related Experiment Video
Updated: Jan 7, 2026

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
Published on: July 24, 2019
Racial and Ethnic Diversity in Clinical Trials for Disease Modifying Drugs in Parkinson Disease: A Systematic Review
Farley Reis Rodrigues1, Gabriel Bolner2, Giovana Barros E Silva Ribeiro3
1Federal University of Vicosa, Viçosa, Brazil.
Background:
There is a historic underrepresentation of non-White participants in Parkinson's Disease (PD) research, although this has not been explored in trials for potential disease-modifying therapies.
Objective:
To evaluate the representation of racial/ethnic minority patients enrolled in double-blind, randomized, placebo-controlled clinical trials (DBRCTs) for PD.
Methods:
A systematic search of four electronic databases was performed. DBRCTs evaluating pharmacological therapies for disease modification in PD were included. Data extraction followed PRISMA guidelines. We computed demographic data with pooled prevalence and 95% confidence intervals (CIs).
Results:
Among 37 DBRCTs and 11,022 patients, 19 studies (51.4%) reported race/ethnicity, being 1.4% Asian, 0.19% Black, and 0.17% Hispanic. Pooled prevalence of participants identified as White in clinical trials was 98% (CI 0.97-0.99, P < 0.001).
Conclusion:
Racial and ethnic minorities were disproportionately underrepresented in DBRCTs for potential disease-modifying therapies for PD. Additional efforts are required to increase the racial and ethnic representation in such studies.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease: Overview
Clinical Trials: Overview
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Clinical Trials
There are four phases in a clinical trial. A phase one...
Neural Regulation

